X-Cell Medical

X-Cell Medical was a clinical-stage medical technology company focused on the development of next-generation drug-eluting stents (DES) for cardiovascular applications. The company's lead program utilized 17-beta-estradiol as an anti-restenotic agent, designed to promote healthy endothelial growth and reduce the risk of sub-acute thrombosis, a common complication of first-generation DES. By leveraging the natural properties of estrogen to enhance vessel healing, X-Cell Medical aimed to provide a safer alternative to stents that used more aggressive antiproliferative drugs. The company advanced its lead candidate into first-in-human clinical trials and was supported by life science venture capital firms such as Forbion Capital Partners.